Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

计划入组 32 人 · 首次发布于 2021 年 8 月 2 日

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

计划入组 61 人 · 首次发布于 2018 年 10 月 9 日

‘A clinical trial to test the safety and immune responses from the BG505 SOSIP.664 gp140 HIV vaccine in development’.

计划入组 60 人

Two trimeric HIV envelope proteins vaccine

763SIP8/MPLA-5 vaccine

Recombinant HIV-1 envelope protein conM SOSIP.v7 gp140 vaccine (Academisch Medisch Centrum)

Protein Sciences Corporation

United States

Worcester HIV Vaccine

United States

HIV VACCINE TRIALS NETWORK

United States

Single-Dose HIV Vaccine Candidate Induces Neutralizing Antibodies in Nonhuman Primates

Accelerated Manufacturing Platform Enables Rapid HIV Vaccine Production for Clinical Trials

Urticaria Emerges as Concern in Phase 1 Trial of HIV mRNA Vaccines